Porownywarka
5-Amino-1MQ vs AOD-9604 side-by-side
Zestaw do czterech peptydów według statusu dowodów, mechanizmów, dawkowania z badań, skutków ubocznych i referencji.
Porownywarka
Zestaw do czterech peptydów według statusu dowodów, mechanizmów, dawkowania z badań, skutków ubocznych i referencji.
Wybrane (2/4)
Udostępnij porównanie peptydów
| Wlasciwosc | 5-Amino-1MQ | AOD-9604 |
|---|---|---|
| Kategoria | Redukcja masy | Redukcja masy |
| Znany tez jako | 5-amino-1-methylquinolinium, NNMT Inhibitor | Anti-Obesity Drug 9604, Tyr-hGH Fragment 177-191 |
| Zatwierdzony przez FDA | Nie | Nie |
| Status kliniczny | Preclinical research; no published human trials reported in the supplied source
| Clinical trials completed without FDA approval; source also reports Sept 2024 FDA Category 2 removal, expected Category 1 reclassification activity in 2026, and GRAS status.
|
| Czego oczekiwac | Fat metabolism, cellular energy, body composition | Fat loss, body composition, localized fat reduction |
| Jak dziala | 5-Amino-1MQ is described in the supplied evidence as an inhibitor of NNMT, the enzyme nicotinamide N-methyltransferase. The proposed model is that lowering NNMT activity may affect adipocyte metabolism through nicotinamide, NAD+ and SAM-related pathways, potentially shifting energy handling in fat tissue. The cited mouse work reported increases in intracellular NAD+ and SAM after NNMT inhibition, but the source does not provide human trial confirmation for these effects. | AOD-9604 is described as a modified fragment of human growth hormone designed around the hormone's fat-metabolism region rather than the broader growth-hormone activity profile. The source reports lab and animal findings consistent with increased lipolysis and reduced lipogenesis. It also reports no meaningful IGF-1 increase, no glucose-metabolism harm in reviewed human safety evidence, and no settled receptor explanation, so the mechanism remains proposed rather than confirmed. |
| Typowe dawkowanie | 50-75 mg daily · Once daily, morning · 4-6 weeks on, 2-4 weeks off | 300 mcg daily · Once daily, usually morning fasted |
| Dawkowanie z badań | 20 mg/kg/day (mice) · 4-6 weeks (cycling recommended) · Subcutaneous injection or oral | 250-500 mcg daily · 12-24 weeks in studies · Subcutaneous injection or oral |
| Typowy czas trwania | 4-6 weeks (cycling recommended) | 12-24 weeks in studies |
| Podanie | Subcutaneous injection or oral | Subcutaneous injection or oral administration reported in studies |
| Timing | Morning, fasted With or without food | Morning, fasted Empty-stomach use reported |
| Poziom dowodów | Przedkliniczne | Badania kliniczne |
| Mozliwe skutki uboczne |
+2 więcej
|
+4 więcej
|
| Podsumowanie researchu | The supplied source highlights preclinical work on small-molecule NNMT inhibitors in diet-induced obese mice. In that work, treated animals reportedly lost about 5% of baseline weight over roughly 11 days, had lower white adipose mass and reduced circulating cholesterol, while food intake did not change. The source characterizes the overall evidence base as animal and cell research and states that published human trials demonstrating fat loss, increased energy expenditure or long-term safety were not available. The source separately cautions that vendor-promoted percentages for human fat loss remain unsupported by clinical trial evidence. | The supplied source presents a mixed evidence picture. It describes supportive cell and animal findings for fat-metabolism effects, then reports roughly six randomized, double-blind, placebo-controlled human trials involving about 900 participants. A cited safety review is summarized as finding good tolerability, no IGF-1 elevation, no glucose-metabolism harm, and no detectable antibodies. However, the source also states that the largest Phase IIb obesity trial did not beat placebo on its main weight-loss endpoint and that Metabolic Pharmaceuticals halted development around 2007. |
| Referencje | ||
| Pełny profil | Zobacz szczegóły | Zobacz szczegóły |
Zapisz to porównanie
Trzymaj ten zestaw researchowy pod reka na darmowym koncie PeptiGuide.
Zapisz porównanie - darmowe kontoTrackuj swoja ścieżkę peptydówa
Zamien research w prywatny log protokołu, gdy będziesz gotowy.
Trackuj ścieżkę peptydówaWyłącznie edukacyjnie. Te informacje są agregowane z publicznych badań i raportów społeczności. To nie jest poradą medyczną, a informacje o dawkowaniu są opisowe, nie rekomendacyjne. Zawsze konsultuj się z wykwalifikowanym specjalistą ochrony zdrowia.